Firms that began work on vaccines for other diseases such as Zika and Sars had their fingers burnt. On the other hand, the market for flu’ jabs, which is worth several billion dollars a year, suggests that if Covid-19, like flu, is here to stay and requires annual booster jabs, then it could be profitable for the firms that come up with the most effective, and most cost-effective products.

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending

Log in with your credentials

Forgot your details?